Antibody-based therapeutics play a vital role in treating a wide range of diseases, but their manufacture can be complex, requiring efficient purification strategies to support product quality and ...

The next generation of engineered monoclonal antibodies presents new challenges in downstream processing due to increased aggregate formation. These aggregates can compromise product efficacy, elevate ...

Biointron can produce antibodies from gene synthesis to antibody purification in as little as two weeks, sometimes even a week, depending on the scale. “It’s very common to take five to six ...

Increase in R&D expenditure in biopharmaceuticals, rise in demand for biologics and monoclonal antibodies (mAbs), and rise in adoption of biosimilars are the major factors that drive the growth of the ...